clinical trial for ban2401 in early alzheimer’s: combining adcoms and bayesian statistics
Published 6 years ago • 818 plays • Length 10:19Download video MP4
Download video MP3
Similar videos
-
11:32
outstanding amyloid response to ban2401: slowing progression in early alzheimer’s
-
0:42
ban2401 study: early alzheimer’s disease - first choice neurology - dr. jeffrey gelblum
-
1:31
phase ii study of lecanemab in early ad
-
4:57
open-label extension study of lecanemab in early alzheimer’s disease
-
1:54
what’s next for clinical trials in alzheimer’s disease?
-
2:51
cautious optimism for early results of new alzheimer’s drug
-
59:44
clinical trials you can make a difference! oct 14, 2023
-
1:05
alzheimer's disease therapy - clinical trials (5 of 11)
-
0:53
💊bim - there is hope: joining alzheimer's clinical trials with dr. meghan riddle
-
4:23
a post-hoc analysis of lipididiet: adcoms, gst & bha
-
1:32
major ongoing clinical trials in ad: aducanumab, donanemab & lecanemab
-
0:56
what is different about this clinical trial - first choice neurology - dr. jeffrey gelblum
-
1:55
clinical trial: canakinumab for alzheimer's disease (nct04795466)
-
30:50
a bayesian industry approach to phase 1 combination trials in oncology - satrajit roychoudhury
-
41:51
accelerating clinical trials: innovative clinical trial designs, with an intro to bayesian thinking
-
19:46
analyzing the clinical data for aduhelm, biogen's controversial alzheimer's drug
-
16:08
using bayesian statistics for clinical research | pharmalex
-
2:53
fda approves controversial new alzheimer's drug that had clinical trials in indianapolis
-
26:37
bayesian analysis methodology - how to analyse multiple endpoint in clinical trials